Study: NCT05182073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT576 (Allogenic CAR NK cells with BCMA expression)
Description: Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT576 (Allogenic CAR NK cells with BCMA expression)
Description: Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT576 (Allogenic CAR NK cells with BCMA expression)
Description: Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT576 (Allogenic CAR NK cells with BCMA expression)
Description: Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Anti-CD38 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Anti-CD38 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning Agent